10.1016/j.eprac.2024.11.017 86 YabutJ
Evidence was reported according to the neuropsychiatric condition under investigation: cognitive disorders (dementia, Parkinsons disease), substance-use disorders, psychotic disorders, mood and anxiety disorders, and eating disorderseach subdivided into pre-clinical and mechanistic evidence, and clinical evidence, the latter reported following a hierarchy of evidence (that is, meta-analyses, clinical trials, observational studies, case series)
Implications for employers and drugmakers: Lillys move puts a major manufacturer behind the employer GLP-1 cost-sharing model that smaller players like GoodRx and Waltz Health have launched on their own
Yes, but pauses should always be supervised by a provider to avoid disrupting treatment progress Yes, compounded semaglutide can be a good starting option because it allows gradual and customized dosing
However, repeatedly exposing it to temperature swings isn't ideal
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
